Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy

Molecular Genetics and Metabolism

Volumn 101, Issue 4, 2010, Pages 332-337

  Barker, Piers C A ^a   Pasquali, Sara K ^a   Darty, Stephen ^a   Ing, Richard J ^a   Li, Jennifer S ^a   Kim, Raymond J ^a   DeArmey, Stephanie ^a   Kishnani, Priya S ^a   Campbell, Michael J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiac magnetic resonance imaging; Delayed enhancement; Echocardiography; Enzyme replacement therapy; Pompe disease

Indexed keywords

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; INFANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY;

ALPHA-GLUCOSIDASES; CARDIOMYOPATHIES; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT THERAPY; FEMALE; FIBROSIS; GLYCOGEN STORAGE DISEASE TYPE II; HEART; HEART VENTRICLES; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM;

EID: 78649321995     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.07.011     Document Type: Article

References (41)

1. Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase deficiency). The Metabolic and Molecular Basis of Inherited Disease 2001, 3389-3420. McGraw Hill, New York. C.R.S. (Ed.).
2. Kishnani P.S., Howell R.R. Pompe disease in infants and children. J. Pediatr. May 2004, 144(5 Suppl):S35-S43.
3. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. May 2006, 148(5):671-676.
4. van den Hout H.M., Hop W., van Diggelen O.P., Smeitink J.A., Smit G.P., Poll-The B.T., Bakker H.D., Loonen M.C., de Klerk J.B., Reuser A.J., van der Ploeg A.T. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics Aug 2003, 112(2):332-340.
5. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., De la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology Jan 9 2007, 68(2):99-109.
6. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., Mackey J., Kishnani P., Smith W., McVie-Wylie A., Sullivan J.A., Hoganson G.E., Phillips J.A., Schaefer G.B., Charrow J., Ware R.E., Bossen E.H., Chen Y.T. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. Mar-Apr 2001, 3(2):132-138.
7. Kishnani P.S., Nicolino M., Voit T., Rogers R.C., Tsai A.C., Waterson J., Herman G.E., Amalfitano A., Thurberg B.L., Richards S., Davison M., Corzo D., Chen Y.T. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J. Pediatr. Jul 2006, 149(1):89-97.
8. Klinge L., Straub V., Neudorf U., Schaper J., Bosbach T., Gorlinger K., Wallot M., Richards S., Voit T. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul. Disord. Jan 2005, 15(1):24-31.
9. van der Ploeg A.T., Clemens P.R., Corzo D., Escolar D.M., Florence J., Groeneveld G.J., Herson S., Kishnani P.S., Laforet P., Lake S.L., Lange D.J., Leshner R.T., Mayhew J.E., Morgan C., Nozaki K., Park D.J., Pestronk A., Rosenbloom B., Skrinar A., van Capelle C.I., van der Beek N.A., Wasserstein M., Zivkovic S.A. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N. Engl. J. Med. Apr 15 2010, 362(15):1396-1406.
10. Levine J.C., Kishnani P.S., Chen Y.T., Herlong J.R., Li J.S. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe Disease. Pediatr. Cardiol. Nov 2008, 29(6):1033-1042.
11. Ansong A.K., Li J.S., Nozik-Grayck E., Ing R., Kravitz R.M., Idriss S.F., Kanter R.J., Rice H., Chen Y.T., Kishnani P.S. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet. Med. May 2006, 8(5):297-301.
12. McDowell R., Li J.S., Benjamin D.K., Morgan C., Becker A., Kishnani P.S., Kanter R.J. Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. Genet. Med. Oct 2008, 10(10):758-762.
13. Frustaci A., Chimenti C. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation Sep 18 2007, 116(12):e350-e351.
14. Joshi S.B., Ahmar W., Lee G., Aggarwal A. Fabry's disease presenting as ventricular tachycardia and left ventricular 'hypertrophy'. Eur. J. Echocardiogr. Sep 2008, 9(5):697-699.
15. Shah J.S., Hughes D.A., Sachdev B., Tome M., Ward D., Lee P., Mehta A.B., Elliott P.M. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am. J. Cardiol. Sep 15 2005, 96(6):842-846.
16. Imbriaco M., Spinelli L., Cuocolo A., Maurea S., Sica G., Quarantelli M., Pisani A., Liuzzi R., Cianciaruso B., Sabbatini M., Salvatore M. MRI characterization of myocardial tissue in patients with Fabry's disease. AJR Am. J. Roentgenol. Mar 2007, 188(3):850-853.
17. Moon J.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J., Leed P.J., Elliott P.M. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur. Heart J. Dec 2003, 24(23):2151-2155.
18. Moon J.C., Sheppard M., Reed E., Lee P., Elliott P.M., Pennell D.J. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J. Cardiovasc. Magn. Reson. 2006, 8(3):479-482.
19. Ing R.J., Cook D.R., Bengur R.A., Williams E.A., Eck J., Dear Gde L., Ross A.K., Kern F.H., Kishnani P.S. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr. Anaesth. Jun 2004, 14(6):514-519.
20. Wang L.Y., Ross A.K., Li J.S., Dearmey S.M., Mackey J.F., Worden M., Corzo D., Morgan C., Kishnani P.S. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr. Anaesth. Aug 2007, 17(8):738-748.
21. Hori Y., Yamada N., Higashi M., Hirai N., Nakatani S. Rapid evaluation of right and left ventricular function and mass using real-time true-FISP cine MR imaging without breath-hold: comparison with segmented true-FISP cine MR imaging with breath-hold. J. Cardiovasc. Magn. Reson. Jul 2003, 5(3):439-450.
22. Bellenger N.G.P.D. Cardiovascular Magnetic Resonance 2002, Ny Churchill Livingstone, New York.
23. Snider A.R.S.G., Ritter S.B. Echocardiography in Pediatric Heart Disease 1997, Mosby-Year Book. 2nd ed.
24. Li J.S.C.Y., Morgan C., Kishnani P.S. Developments in the Treatment of Pompe Disease. U.S. Cardiovas. Dis. 2006, 1-4.
25. Katz J., Milliken M.C., Stray-Gundersen J., Buja L.M., Parkey R.W., Mitchell J.H., Peshock R.M. Estimation of human myocardial mass with MR imaging. Radiology Nov 1988, 169(2):495-498.
26. Devlin A.M., Moore N.R., Ostman-Smith I. A comparison of MRI and echocardiography in hypertrophic cardiomyopathy. Br. J. Radiol. Mar 1999, 72(855):258-264.
27. Stewart G.A., Foster J., Cowan M., Rooney E., McDonagh T., Dargie H.J., Rodger R.S., Jardine A.G. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int. Dec 1999, 56(6):2248-2253.
28. Kim R.J., Shah D.J., Judd R.M. How we perform delayed enhancement imaging. J. Cardiovasc. Magn. Reson. Jul 2003, 5(3):505-514.
29. Kim H.W., Farzaneh-Far A., Kim R.J. Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. J. Am. Coll. Cardiol. Dec 29 2009, 55(1):1-16.
30. Klem I., Heitner J.F., Shah D.J., Sketch M.H., Behar V., Weinsaft J., Cawley P., Parker M., Elliott M., Judd R.M., Kim R.J. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J. Am. Coll. Cardiol. 2006 Apr 18, 47(8):1630-1638.
31. Senthilkumar A., Majmudar M.D., Shenoy C., Kim H.W., Kim R.J. Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance. Heart Fail. Clin. Jul 2009, 5(3):349-367. (vi).
32. Sechtem U., Mahrholdt H., Vogelsberg H. Cardiac magnetic resonance in myocardial disease. Heart Dec 2007, 93(12):1520-1527.
33. De Cobelli F., Esposito A., Belloni E., Pieroni M., Perseghin G., Chimenti C., Frustaci A., Del Maschio A. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. Am. J. Roentgenol. March 1 2009, 192(3):W97-W102.
34. Beer M., Weidemann F., Breunig F., Knoll A., Koeppe S., Machann W., Hahn D., Wanner C., Strotmann J., Sandstede J. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am. J. Cardiol. May 15 2006, 97(10):1515-1518.
35. Silva C., Moon J.C., Elkington A.G., John A.S., Mohiaddin R.H., Pennell D.J. Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience. J. Cardiovasc. Med. (Hagerstown) Dec 2007, 8(12):1076-1079.
36. Leonardi S., Raineri C., De Ferrari G.M., Ghio S., Scelsi L., Pasotti M., Tagliani M., Valentini A., Dore R., Raisaro A., Arbustini E. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur. Heart J. August 2 2009, 30(16):2003-2010.
37. Hughes D.A., Elliott P.M., Shah J., Zuckerman J., Coghlan G., Brookes J., Mehta A.B. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart Feb 2008, 94(2):153-158.
38. Koskenvuo J.W., Hartiala J.J., Nuutila P., Kalliokoski R., Viikari J.S., Engblom E., Penttinen M., Knuuti J., Mononen I., Kantola I.M. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J. Inherit. Metab. Dis. Jun 2008, 31(3):432-441.
39. Sun B., Bird A., Young S.P., Kishnani P.S., Chen Y.T., Koeberl D.D. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am. J. Hum. Genet. Nov 2007, 81(5):1042-1049.
40. Myozyme, package insert. Available from: http://www.myozyme.com/PDF/mz_pi.pdf.
41. Kishnani P.S., Goldenberg P.C., DeArmey S.L., Heller J., Benjamin D., Young S., Bali D., Smith S.A., Li J.S., Mandel H., Koeberl D., Rosenberg A., Chen Y.T. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. Jan 2010, 99(1):26-33.